CN106722978A - A kind of health food for improving cognitive ability and memory - Google Patents
A kind of health food for improving cognitive ability and memory Download PDFInfo
- Publication number
- CN106722978A CN106722978A CN201510822253.1A CN201510822253A CN106722978A CN 106722978 A CN106722978 A CN 106722978A CN 201510822253 A CN201510822253 A CN 201510822253A CN 106722978 A CN106722978 A CN 106722978A
- Authority
- CN
- China
- Prior art keywords
- parts
- health food
- memory
- cognitive ability
- improving cognitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000015654 memory Effects 0.000 title claims abstract description 25
- 235000013402 health food Nutrition 0.000 title claims abstract description 21
- 230000003930 cognitive ability Effects 0.000 title claims abstract description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 8
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 7
- 208000000655 Distemper Diseases 0.000 claims abstract description 7
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 7
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 4
- 229930195725 Mannitol Natural products 0.000 claims abstract description 4
- 239000004383 Steviol glycoside Substances 0.000 claims abstract description 4
- 239000000594 mannitol Substances 0.000 claims abstract description 4
- 235000010355 mannitol Nutrition 0.000 claims abstract description 4
- 229930182488 steviol glycoside Natural products 0.000 claims abstract description 4
- 235000019411 steviol glycoside Nutrition 0.000 claims abstract description 4
- 150000008144 steviol glycosides Chemical class 0.000 claims abstract description 4
- 235000019202 steviosides Nutrition 0.000 claims abstract description 4
- 239000004615 ingredient Substances 0.000 claims abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 11
- 230000001149 cognitive effect Effects 0.000 description 9
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 241000218628 Ginkgo Species 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000003931 cognitive performance Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007595 memory recall Effects 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of health food for improving cognitive ability and memory, the following component comprising following parts by weight：215 parts of 100 parts of phosphatidylserine powder and DHA algal oil-bound distemper, also including the adjunct ingredient of following parts by weight：3 parts of 300 parts of microcrystalline cellulose (MCC), 240 parts of mannitol, 140 parts of D-sorbite, 2 parts of steviol glycoside and milk-taste essence.Health food disclosed by the invention combines phosphatidylserine and DHA, realizes the irrealizable synergy of folk prescription institute, can be good at improving cognitive ability and memory.
Description
Technical field
The present invention relates to a kind of health food, more particularly to a kind of health food for improving cognitive ability and memory.
Background technology
Cognitive ability refers to human brain processing, storage and the ability for extracting information, i.e. people to the composition of things, performance and his thing
The assurance ability of relation, the power, developing direction and basic law of development.It is that successfully completion activity is most important for people
Mental condition.Consciousness, memory, attention, the ability of mind and imagination are considered as cognitive ability.
Content and the ability of experience that memory is memorize, holding, recognize and reappear objective things again is reflected.Memory is people
One kind of class intellectual activities, belongs to the category of psychology or brain science.Memory represent a people to the past activity, impression,
The impression accumulation of experience.
Alzheimer disease (AD) is a kind of nervous system degenerative disease for carrying out sexual development of onset concealment.Clinically with note
Recall obstacle, aphasia, appraxia, agnosia, the infringement of visual space technical ability, perform function obstacle and personality and behavior change etc. comprehensive
Dementia performance is characterized, and the cause of disease is unknown so far.Patient was sent out within 65 years old in the past, claimed alzheimer's disease；Claim old age with sequela person within 65 years old
Property it is dull-witted.Dementia refers to chronic acquired progressive syndrome of intelligent disorder.It is clinically main with the slow hypophrenia for occurring
Feature, with different degrees of personality change.It is one group of clinical syndrome, rather than a kind of independent disease.
Prior art is more to constitute health food with ginkgo, multivitamin, antioxidant, caffeine or DHA folk prescriptions.Ginkgo,
The product such as multivitamin and antioxidant is the extensive anti-oxidant and trophism in the whole body, acts on whole body, is not specific to brain
Portion's nutrition, and effect is slow.Coffee acts on short because temporary brain capability improving is acted on, and the duration is very limited, and
Long-term persistently to take or cause sleep disordered, the effect such as metabolic disorder, caffeine need to differentiate source, and synthetic caffeine is to human body
There is stronger stimulation.
The content of the invention
In order to solve the above technical problems, the invention provides a kind of health food for improving cognitive ability and memory, to be reached for
The health food of the exclusive exploitation of brain cognitive function, can effectively improve the purpose of cognitive ability and memory.
To reach above-mentioned purpose, technical scheme is as follows：
A kind of health food for improving cognitive ability and memory, the following component comprising following parts by weight：Phosphatidylserine
215 parts of 100 parts of powder and DHA algal oil-bound distemper.
In such scheme, the health food also adjunct ingredient including following parts by weight：Microcrystalline cellulose (MCC) 300
3 parts of part, 240 parts of mannitol, 140 parts of D-sorbite, 2 parts of steviol glycoside and milk-taste essence.
In further technical scheme, after the health food is by the way that said components are well mixed, 80% alcohol granulation is used, done
Dry, the magnesium stearate for adding prepared particle weight 0.5% is mixed, and compressing tablet prepares piece agent.
In such scheme, the mass fraction containing phosphatidylserine is 50-60% in the phosphatidylserine powder.
In such scheme, the mass fraction containing DHA is 7-10% in the DHA algal oil-bound distemper.
By above-mentioned technical proposal, the health food that the present invention is provided is the exclusive exploitation of brain cognitive function, is acted on through clinical test
Checking is effective, and phosphatidylserine is the necessary material that brain neuron cell inner membrance exercises specific function, and to neurotransmitter regulator
Play facilitation, the nutritious cerebrations of DHA, and the synthesis of internal itself phosphatidylserine can be promoted, both are combined
Use the outer benefit and interior life that can realize brain phospholipid acyl serine.
Specific embodiment
The technical scheme in the embodiment of the present invention will be clearly and completely described below.
The invention provides a kind of health food for improving cognitive ability and memory, specific embodiment is as follows：
Embodiment 1：
100 parts of phosphatidylserine powder, 215 parts of DHA algal oil-bound distemper, 300 parts of microcrystalline cellulose (MCC), mannitol 240
Part, 140 parts of D-sorbite, 2 parts of steviol glycoside and 3 parts of milk-taste essence；Contain phosphatidyl silk ammonia in phosphatidylserine powder
The mass fraction of acid is 55%, and the mass fraction containing DHA is 8% in DHA algal oil-bound distemper.After said components are well mixed, use
80% alcohol granulation, is dried, and the magnesium stearate for adding prepared particle weight 0.5% is mixed, and compressing tablet prepares piece agent.
Tablet obtained in above-described embodiment 1 is carried out into memory improves experiment.
Subject：
Recruit the masculinity and femininity volunteer (the range of age 50-90 Sui) with memory disorder of certain geriatric hospital examination.
Examination include medical archive, physical examination, Routine Test Lab inspection and including use computer neuropsychological assessment tool.With memory
Subject's (allowing maximum beyond conventional more than 4 points) of power obstacle is showed with score value, and score value is within conventional data or low
In the standard deviation of routine ± 1.5 times.
The situation that volunteers are left out：The sign or history of spiritedness entanglement；Unconsciousness has other disturbances of consciousness；
There is the sign-depression (SDS simplifies version test score >=4) of senile dementia；Cognitive any nerveous system of deterioration may be produced
System disease (including Parkinson's disease, apoplexy, intracranial hemorrhage, including local cerebral disease such as brain tumor and normal pressure hydrocephalus)；
Infection or inflammatory brain disease (including virus, fungi, or venereal because)；Cognitive any uncontrollable doctor of deterioration can be caused
Treatment obstacle (including hypertension, ephrosis, respiratory disorder, heart disease, hepatopathy, diabetes, endocrine, it is metabolized or haematological disorders
Disease, the malignant tumour do not alleviated more than more than 2 years)；Cognition deteriorate before head injury, or have alcohol and drug abuse
Record, these tested volunteers are excluded.If taking several drugses or replenishers in examination disease or in the treatment previous moon
To influence cognitive performance, have allergies or to soybean allergy, or cognitive ability can not be tested with Jew's language, all arranged
Except outside.
Experimental design and dosage：
This experimental design is single center and open label.All participants are cognitive by evaluation after the treatment of 12 weeks according to baseline
Performance.Cognitive performance is assessed by computer cognition assessment tool.Participant takes 2 tablets, Time of Administration 12 weeks daily.
Cognition assessment：
The test content of packet includes：
Using the cognitive assessment software systems of NexSig companies, following test is carried out：
1st, plus sige is recognized, subject faces a computer, when occurring plus sige on screen, by lower keyboard specific keys.
2nd, special pattern is recognized, subject must identify distinguished one from the three of screen display kinds of patterns.
3rd, recall pattern, provide the pictures of subject one, the pattern identification that then will be previously seen from three kinds of pictures is out.
4th, numerical chracter replacement test, subject according to solid plate by numeral and Symbol matching.
5th, numeric string memory, subject carries on the back out a numeric string (increasing digital string length every time) according to tandem or reverse order.
6th, postpone pattern to recall, subject is apprised of requirement and remembers several simple patterns, needed after 10 minutes from a pile pattern
Find out the pattern for being required to remember.
Before each test, every subject needs to be familiar with the task of problem with a brief training module, and test is limited to 30-45
Minute, including the training stage.
Each item-dividing test carries out (such as by any key from input set of number) with the order that difficulty is incremented by, and each single item packet test is real
It is the service of following training in matter.All of test has multiple versions, to eliminate because being imitated caused by management organization's difference
Fruit difference.Score is obtained by algorithm, in module, every group of result is separated and disposed.Based on module and the number collected
Amount increases, and the software can provide the fraction of test.
Result based on individual task, 8 general cognitive fractions are calculated, and these total performances include：Memory identification, memory
Recall, executive capability, brain flexibility, focus on, sustaining attention, visual space learning ability and space are remembered in short term
Recall power.
Statistical method：
The computer fraction collected in baseline and after 6,12 weeks depends on repeated-measures analysis model (RM-ANOVA).For student
The independent sample of t- test comparisons analysis is tested the conspicuousness issued after examination and approval in present repeated-measures analysis.This is done to determine baseline
And the significance difference opposite sex between the computer fraction between 6 weeks and baseline and 12 weeks.
As a result：
Study population：
26 experimenters (7 male 19 female) complete clinical test, and average age is 74.6 ± 1.7, wherein 46% subject is
Wedding, average educational age：13.8±0.01.
Cognitive result：
Present assessment by computer cognition result in table 1, cognitive comprehensive score is not with baseline and takes the tablet 6 weeks and 12 of preparation
It is defined after week.Repeated-measures analysis model (RM-ANOVA) confirm memory identification (P=0.007), memory recall (P=0.015),
The aspect such as executive capability (P=0.013) and brain flexibility (P=0.029) significantly improves the effect of score.Simultaneously it has also been found that right
Focus on, sustaining attention, visual space learning ability and space short term memory also increase.
The subject of table 1 tests soybean source phosphatidylserine to Cognitive Effects
| Cognitive comprehensive score | Baseline | 6 weeks | 12 weeks | P values |
| Memory identification | 80.60±2.11 | 86.24±2.07 | 87.36±1.54 | 0.007 |
| Memory is recalled | 73.52±2.55 | 81.12±2.64 | 82.32±2.30 | 0.015 |
| Executive capability | 72.36±4.62 | 79.16±4.36 | 82.64±3.69 | 0.013 |
| Brain flexibility | 73.12±4.64 | 79.32±4.35 | 82.44±3.53 | 0.029 |
| Focus on | 85.20±2.46 | 88.24±2.45 | 90.28±1.91 | 0.076 |
| Sustaining attention | 82.04±3.18 | 86.00±2.52 | 87.76±1.80 | 0.100 |
| Visual space learning ability | 60.72±2.65 | 66.40±4.08 | 67.88±3.67 | 0.170 |
| Space short term memory | 58.44±2.93 | 63.44±4.52 | 64.32±4.17 | 0.423 |
The foregoing description of the disclosed embodiments, enables professional and technical personnel in the field to realize or uses the present invention.To these
Various modifications of embodiment will be apparent for those skilled in the art, generic principles defined herein
Can realize in other embodiments without departing from the spirit or scope of the present invention.Therefore, the present invention will not be by
It is limited to the embodiments shown herein, and is to fit to consistent with principles disclosed herein and features of novelty most wide
Scope.
Claims (5)
1. a kind of health food for improving cognitive ability and memory, it is characterised in that the following component comprising following parts by weight：
215 parts of 100 parts of phosphatidylserine powder and DHA algal oil-bound distemper.
2. a kind of health food for improving cognitive ability and memory according to claim 1, it is characterised in that the guarantor
The health food also adjunct ingredient including following parts by weight：300 parts of microcrystalline cellulose (MCC), 240 parts of mannitol, sorb
3 parts of 140 parts of sugar alcohol, 2 parts of steviol glycoside and milk-taste essence.
3. a kind of health food for improving cognitive ability and memory according to claim 2, it is characterised in that the guarantor
After health food is by the way that said components are well mixed, 80% alcohol granulation is used, dried, add prepared particle weight 0.5%
Magnesium stearate is mixed, and compressing tablet prepares piece agent.
4. a kind of health food for improving cognitive ability and memory according to claim 1, it is characterised in that the phosphorus
The mass fraction containing phosphatidylserine is 50-60% in acyl serine powder.
5. a kind of health food for improving cognitive ability and memory according to claim 1, it is characterised in that described
The mass fraction containing DHA is 7-10% in DHA algal oil-bound distemper.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510822253.1A CN106722978A (en) | 2015-11-19 | 2015-11-19 | A kind of health food for improving cognitive ability and memory |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510822253.1A CN106722978A (en) | 2015-11-19 | 2015-11-19 | A kind of health food for improving cognitive ability and memory |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106722978A true CN106722978A (en) | 2017-05-31 |
Family
ID=58963375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510822253.1A Pending CN106722978A (en) | 2015-11-19 | 2015-11-19 | A kind of health food for improving cognitive ability and memory |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106722978A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107125752A (en) * | 2017-06-14 | 2017-09-05 | 成都新柯力化工科技有限公司 | A kind of phosphatidylserine oral liquid and preparation method for promoting memory function |
| CN107149146A (en) * | 2017-06-14 | 2017-09-12 | 芜湖福民生物药业股份有限公司 | Lozenge containing phosphatidylserine and preparation method thereof |
| CN107373488A (en) * | 2017-07-20 | 2017-11-24 | 钟祥亿源生物科技有限公司 | One kind protection nervous system, improve memory, prevent senile dementia composition |
| CN108030085A (en) * | 2017-12-29 | 2018-05-15 | 广州美耕食品有限公司 | Phosphatidylserine DHA spina date seed pieces and preparation method thereof |
| WO2019131444A1 (en) * | 2017-12-26 | 2019-07-04 | 花王株式会社 | Cognitive function improvement agent |
| CN110973645A (en) * | 2019-12-26 | 2020-04-10 | 广州华农大营养科技有限公司 | Protein powder with brain nerve nutrition function |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885310A (en) * | 2012-10-19 | 2013-01-23 | 中科乐仁（北京）科技发展有限公司 | Health care food composition capable of assisting in improving memory, and preparation method thereof |
| CN103315299A (en) * | 2013-07-08 | 2013-09-25 | 北京东方红航天生物技术股份有限公司 | Health-care food with function of enhancing immunity and memory |
| CN103609752A (en) * | 2013-12-02 | 2014-03-05 | 内蒙古伊利实业集团股份有限公司 | Composition for improving cognitive function of brain, and preparation method and application thereof |
-
2015
- 2015-11-19 CN CN201510822253.1A patent/CN106722978A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885310A (en) * | 2012-10-19 | 2013-01-23 | 中科乐仁（北京）科技发展有限公司 | Health care food composition capable of assisting in improving memory, and preparation method thereof |
| CN103315299A (en) * | 2013-07-08 | 2013-09-25 | 北京东方红航天生物技术股份有限公司 | Health-care food with function of enhancing immunity and memory |
| CN103609752A (en) * | 2013-12-02 | 2014-03-05 | 内蒙古伊利实业集团股份有限公司 | Composition for improving cognitive function of brain, and preparation method and application thereof |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107125752A (en) * | 2017-06-14 | 2017-09-05 | 成都新柯力化工科技有限公司 | A kind of phosphatidylserine oral liquid and preparation method for promoting memory function |
| CN107149146A (en) * | 2017-06-14 | 2017-09-12 | 芜湖福民生物药业股份有限公司 | Lozenge containing phosphatidylserine and preparation method thereof |
| CN107373488A (en) * | 2017-07-20 | 2017-11-24 | 钟祥亿源生物科技有限公司 | One kind protection nervous system, improve memory, prevent senile dementia composition |
| WO2019131444A1 (en) * | 2017-12-26 | 2019-07-04 | 花王株式会社 | Cognitive function improvement agent |
| CN111511358A (en) * | 2017-12-26 | 2020-08-07 | 花王株式会社 | Agent for improving cognitive function |
| CN108030085A (en) * | 2017-12-29 | 2018-05-15 | 广州美耕食品有限公司 | Phosphatidylserine DHA spina date seed pieces and preparation method thereof |
| CN110973645A (en) * | 2019-12-26 | 2020-04-10 | 广州华农大营养科技有限公司 | Protein powder with brain nerve nutrition function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106722978A (en) | A kind of health food for improving cognitive ability and memory | |
| Huskisson et al. | The influence of micronutrients on cognitive function and performance | |
| Piamjariyakul et al. | Cancer therapy-related symptoms and self-care in Thailand | |
| He et al. | Theta burst magnetic stimulation improves Parkinson’s-related cognitive impairment: a randomised controlled study | |
| Boyle et al. | A combination of green tea, rhodiola, magnesium and B vitamins modulates brain activity and protects against the effects of induced social stress in healthy volunteers | |
| Ayers et al. | A randomised controlled trial of cognitive-behavioural therapy for women with problematic menopausal hot flushes: MENOS 2 trial protocol | |
| Kim et al. | Study on the knowledge and attitudes of falls and awareness of fall risk factors among nursing students | |
| Vanoh et al. | Dietary supplement intake and its association with cognitive function, physical fitness, depressive symptoms, nutritional status and biochemical indices in a 3-year follow-up among community dwelling older adults: a longitudinal study | |
| Roush | Complementary and alternative medicine | |
| Church et al. | Skinny genes' six-week, online, clinical emotional freedom techniques program: durable weight loss and improved psychological symptoms | |
| Chowdhury et al. | Medication taking behavior of students attending a private university in Bangladesh | |
| Vander Stichele et al. | Impact of benefit messages in patient package inserts on subjective drug perception | |
| Jingjing et al. | Effects of aerobic exercise on cognitive function in women with methamphetamine dependence in a detoxification program in Tianjin, China: a randomized controlled trial | |
| Hazavehi et al. | The effect of educational program on mother’s child (6 to 9 month age) for reducing growth failure in Hamadan: applying Health Belief Model (HBM) | |
| Srivastava | Selective enhancement of focused attention by Alpinia galanga in subjects with moderate caffeine consumption | |
| Alsofyani et al. | Prevalence of people that using multivitamins supplementation & experiencing a side effect in Saudi Arabia | |
| JEDRCZAK et al. | Transcendental meditation and health: an overview of experimental research and clinical experience | |
| Rad et al. | Evaluation of the effects of the family-centered empowerment model on the nutrition style and physical activity of patients with asthma | |
| James et al. | Feasibility of a functional medicine approach to slowing clinical cognitive decline in patients over age 55: a multiple case study report | |
| Nahon et al. | Machine Learning exploratory technic detected that men might be up to eight times more affected by the control effect and three times more affected by the placebo effect than women | |
| US20140342022A1 (en) | Natural Product Against Fatigue | |
| Chen et al. | Cordyceps sinensis combined with duloxetine improves sleep symptoms in patients with depression: a randomized, double-blind, placebo-controlled study | |
| Mohammadkhani et al. | Different forms of child abuse and maltreatment, quality of life and general health in parents of abused children | |
| Wang | MITIGATION EFFECT OF HUMAN-COMPUTER INTERACTION ON PEOPLE WITH COGNITIVE IMPAIRMENT IN IMAGE PROCESSING | |
| Dudzinska et al. | Selected forms of therapy for individuals with autism spectrum disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |